| Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner H Xie, J Xu, JH Hsu, M Nguyen, Y Fujiwara, C Peng, SH Orkin Cell stem cell 14 (1), 68-80, 2014 | 325 | 2014 |
| Modeling initiation of Ewing sarcoma in human neural crest cells C von Levetzow, X Jiang, Y Gwye, G von Levetzow, L Hung, A Cooper, ... PloS one 6 (4), e19305, 2011 | 200 | 2011 |
| EED-targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex JHR Hsu, T Rasmusson, J Robinson, F Pachl, J Read, S Kawatkar, ... Cell chemical biology 27 (1), 41-46. e17, 2020 | 163 | 2020 |
| BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression D Douglas, JHR Hsu, L Hung, A Cooper, D Abdueva, J van Doorninck, ... Cancer research 68 (16), 6507-6515, 2008 | 157 | 2008 |
| Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma AL Green, SH Ramkissoon, D McCauley, K Jones, JA Perry, JHR Hsu, ... Neuro-oncology 17 (5), 697-707, 2015 | 66 | 2015 |
| The Diheme Cytochrome c Peroxidase from Shewanella oneidensis Requires Reductive Activation GS Pulcu, KE Frato, R Gupta, HR Hsu, GA Levine, MP Hendrich, SJ Elliott Biochemistry 51 (5), 974-985, 2012 | 44 | 2012 |
| BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma JH Hsu, ER Lawlor Oncogene 30 (17), 2077-2085, 2011 | 40 | 2011 |
| PRMT1-mediated translation regulation is a crucial vulnerability of cancer JHR Hsu, B Hubbell-Engler, G Adelmant, J Huang, CE Joyce, F Vazquez, ... Cancer research 77 (17), 4613-4625, 2017 | 36 | 2017 |
| Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group A Cooper, J van Doorninck, L Ji, D Russell, M Ladanyi, H Shimada, ... Clinical Cancer Research 17 (1), 56-66, 2011 | 28 | 2011 |
| Safety of onartuzumab in patients with solid tumors: Experience to date from the onartuzumab clinical trial program R Morley, A Cardenas, P Hawkins, Y Suzuki, V Paton, SC Phan, ... PloS one 10 (10), e0139679, 2015 | 26 | 2015 |
| Orthoses in patients with brachial plexus injuries. J Perry, J Hsu, L Barber, MM Holler Archives of Physical Medicine and Rehabilitation 55 (3), 134-137, 1974 | 18 | 1974 |
| Diverse, potent, and efficacious inhibitors that target the EED subunit of the polycomb repressive complex 2 methyltransferase SK Bagal, C Gregson, DH O’Donovan, KG Pike, A Bloecher, P Barton, ... Journal of Medicinal Chemistry 64 (23), 17146-17183, 2021 | 15 | 2021 |
| Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase DH O'Donovan, C Gregson, MJ Packer, R Greenwood, KG Pike, ... Bioorganic & Medicinal Chemistry Letters 39, 127904, 2021 | 13 | 2021 |
| Polycomb repressive complex 2 regulates hematopoietic stem cell maintenance and differentiation in a developmental stage-specific manner H Xie, J Xu, JH Hsu, M Nguyen, Y Fujiwara, C Peng, SH Orkin Cell stem cell 14 (1), 68, 2014 | 7 | 2014 |
| Trauma Association of Canada (TAC) Annual Scientific Meeting. The Westin Whistler Resort & Spa, Whistler, BC, Thursday, Apr. 11 to Saturday, Apr. 13, 2013Testing the … G Hoit, C Hinkewich, J Tiao, V Porgo, L Moore, C Wang, B Moffatt, ... Canadian Journal of Surgery 56 (2 Suppl), S1-S42, 2013 | 1 | 2013 |
| Abstract ND06: First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4/6 inhibitors in breast and CCNE1-high cancers CR Denz, M Grondine, J Fan, JHR Hsu, A Jackson, J Robinson, G Guo, ... Cancer Research 84 (7_Supplement), ND06-ND06, 2024 | | 2024 |
| Targeting the cell cycle with AZD8421, a potent and highly selective CDK2 inhibitor CR Denz, M Grondine, J Fan, JHR Hsu, A Jackson, J Robinson, G Guo, ... Cancer Research 84 (6_Supplement), 5730-5730, 2024 | | 2024 |
| Diverse Drug Combinations with an Eed Inhibitor Confer Context-Specific Benefit across Multiple Tumor Types JHR Hsu, S Borodovsky, Y Wang, M San Martin, M Shen, H Woods, ... Blood 138, 2274, 2021 | | 2021 |
| Abstract LB-A09: EED targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex JHR Hsu, T Rasmusson, J Robinson, F Pachl, J Read, S Kawatkar, ... Molecular Cancer Therapeutics 18 (12_Supplement), LB-A09-LB-A09, 2019 | | 2019 |
| Abstract PR03: Prmt1 and Prmt1-dependent translation initiation are critical vulnerabilities of osteosarcoma JHR Hsu, B Hubbell-Engler, G Adelmant, J Perry, G Cowley, J Marto, ... Cancer Research 76 (5_Supplement), PR03-PR03, 2016 | | 2016 |
